Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New point system enhances prognosis for GIST patients

07.02.2005


A research team at the Sahlgrenska Academy at Göteborg University in Sweden has developed a point system for calculating risk that will help physicians determine prognoses, survival rates, and the best methods of treatment for patients suffering from GIST tumors. The findings are being published in the prestigious medical journal Cancer.



GIST is a soft tissue tumor that occurs in the abdomen but differs from gastro-intestinal cancer. Nearly two hundred Swedes are affected every year. Long-term survival rates have been low. GIST tumors can grow very large and occupy a major section of the abdomen. Some tumors weigh as much as five kilos. For many years the only method of treatment was surgery, but over the last four years it is has been possible to combine surgery with new medicinal treatment in the form of the medicine Imatinib. The medicine is administered to inhibit the growth of the tumor and to prevent the emergence of new tumors and metastases.

Of all GIST patients, 44 percent develop highly aggressive tumors that in many cases are fatal. These patients should receive priority for medicinal treatment. The new medicine Imatinib is the first drug that effectively treats patients with malignant GIST.


“GIST tumors have been under-diagnosed. Therefore there is a great risk that patients will not receive optimal treatment. The development of Imatinib offers the first effective medicinal treatment of aggressive GIST. Therefore it has become absolutely essential for pathologists, surgeons, and oncologists to be able to diagnose this tumor correctly and to determine just how aggressive the tumor is in order to provide the best possible care,” says Professor Lars-Gunnar Kindblom, who directed the present study together with Professor Jeanne Meis-Kindblom and Associate Professor Bengt Nilsson.

On the basis of a unique study of all GIST cases in Western Sweden between the years 1983 and 2000, Lars-Gunnar Kindblom’s research team developed a system of points. Using this system it is possible to determine a patient’s prognosis in terms of both survival and the risk of developing new tumors. The system is based how large the tumor is and how quickly it is growing, which is determined by analyzing tissue samples.

The scientists divided the GIST patients into four groups­-extremely low risk, low risk, moderate risk, and high risk­-on the basis of the size of the tumor and an index that calculates how many cells are dividing. Of the 170 patients with GIST tumors classified as extremely low risk, low risk, and moderate risk, only one patient had a tumor that could not be operated on, and three patients had recurrent tumors. This can be compared with the 89 patients with high-risk tumors, among whom 36 had inoperable tumors and 35 developed new tumors after surgery. Among patients with high-risk tumors, 63 percent died as a result of their GIST tumors, as did 83 percent of those who had tumors that had already spread extensively. On the other hand, only one percent of the patients died of GIST among those with extremely low, low, and moderate risk levels.

Furthermore, the study shows that GIST is considerably more common that scientists previously believed. Worldwide, roughly 15 individuals per million develop the disease each year.

Ulrika Lundin | alfa
Further information:
http://www.sahlgrenska.gu.se/index_eng.jsp

More articles from Health and Medicine:

nachricht Speed data for the brain’s navigation system
06.12.2016 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Simple processing technique could cut cost of organic PV and wearable electronics

06.12.2016 | Materials Sciences

3-D printed kidney phantoms aid nuclear medicine dosing calibration

06.12.2016 | Medical Engineering

Robot on demand: Mobile machining of aircraft components with high precision

06.12.2016 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>